THE PHARMACIST S ROLE IN MANAGING PATIENTS WITH ADVANCED TYPE 2 DIABETES
|
|
- Buck Cross
- 5 years ago
- Views:
Transcription
1 FACULTY INFORMATION THE PHARMACIST S ROLE IN MANAGING PATIENTS WITH ADVANCED TYPE 2 DIABETES Presenter: Jennifer Costello, PharmD, BCPS, BC-ADM Ambulatory Care Clinical Pharmacist Internal Medicine Faculty Practice Saint Barnabas Medical Center Livingston, New Jersey Jennifer Costello, PharmD, BCPS, BC-ADM Ambulatory Care Clinical Pharmacist Internal Medicine Faculty Practice Saint Barnabas Medical Center Livingston, NJ Moderator: Elena Beyzarov, PharmD Director of Scientific Affairs Pharmacy Times Office of Continuing Professional Education Plainsboro, New Jersey DISCLOSURES Jennifer Costello, PharmD, BCPS, BC-ADM, has no financial relationships with commercial interests to disclose. Pharmacy Times Office of Continuing Professional Education Planning Staff Judy V. Lum, MPA, Elena Beyzarov, PharmD, and Donna W. Fausak have no financial relationships with commercial interests to disclose. PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. The contents of this webinar may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. Please send all questions or comments concerning this webinar to: CEINFO@pharmacytimes.com. Or You can call and leave a message. All s and messages will be answered within 48-hours in the order that they are received. EDUCATIONAL OBJECTIVES Explore prevalence and pathophysiology, as well as clinical and economic burden related to type 2 diabetes and resultant complications Examine evolving standards of care in type 2 diabetes, including treatment goals that extend beyond A1c to include other essential clinical metrics (eg, A1c, blood pressure, lipid levels) Discuss current management of type 2 diabetes, including updated clinical practice guidelines and incorporation of new therapeutic classes into practice recommendations Develop strategies that address clinical inertia and other barriers to optimal management of type 2 diabetes THE PHARMACIST S ROLE IN MANAGING PATIENTS WITH ADVANCED TYPE 2 DIABETES Jennifer Costello, PharmD, BCPS, BC-ADM Ambulatory Care Clinical Pharmacist Internal Medicine Faculty Practice Saint Barnabas Medical Center Livingston, NJ 1
2 PREVALENCE, PATHOPHYSIOLOGY, AND ECONOMIC BURDEN OF TYPE 2 DIABETES MELLITUS (T2DM) US PREVALENCE OF DIABETES In million people diagnosed with T2DM 8.3% of entire population In children, up to 45% of newly diagnosed cases T2DM, with majority overweight or obese Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; ECONOMIC BURDEN OF DIABETES Annual economic burden associated with diagnosed diabetes in United States estimated to be $174 billion ~ $1 in every $10 healthcare attributed to diabetes FUTURE PREDICTION FOR DIABETES If current trend continues, it is estimated that 1 in every 3 people will be diagnosed with diabetes by year 2050 Dall, TM, Edge Mann, S, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Population Health Management ;12(2): Boyle J, Thompson T, Gregg E, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Population Health Metrics. 2010;8:29. NATURAL HISTORY OF T2 DM Impaired glucose tolerance Undiagnosed diabetes Known diabetes COMPLICATIONS FROM DIABETES Microvascular Kidney disease Macrovascular Peripheral arterial disease (PAD) Insulin resistance Insulin secretion Postprandial glucose Fasting glucose Blindness and eye problems Nervous system disease/neuropathy Heart disease Stroke Microvascular complications Macrovascular complications Adapted from Ramlo-Halsted BA, Edelman SV. Prim Care. 1999;26: Dental disease Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention;
3 TEACHABLE MOMENTS: GOALS Generally, every 1% point drop in A1C can reduce risk of microvascular complications by 40% Blood pressure control reduces risk of cardiovascular disease (heart disease or stroke) among people with diabetes by 33% to 50% Improved control of LDL cholesterol can reduce cardiovascular complications by 20% to 50% In patients with prediabetes, losing 7% of body weight can delay and possibly prevent the disease HEDIS/NCQA INFORMATION Percentage of T2DM patients meeting following goal parameters A1c <7% 30.5% 31.1% 35.4% 35.1% LDL < % 33.3% 41.1% 43.6% BP <130/80 31% 31.8% 30.2% BP <140/80 59% 60.6% 56.2% 59.2% Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; The Healthcare Effectiveness Data and Information Set (HEDIS) Continuous Improvement and the Expansion of Quality Measurement. THE STATE OF HEALTH CARE QUALITY National Committee for Quality Assurance. GUIDELINES TREATMENT GOALS FOR ADULTS WITH DIABETES American Diabetes Association (ADA) A1c: <7% Preprandial: mg/dl American Association of Clinical Endocrinologists (AACE) A1c: 6.5% Preprandial: <110 mg/dl 2-hr Postprandial: <180 mg/dl 2-hr Postprandial: <140 mg/dl Blood Pressure <140 / 80 mm Hg LDL <100 mg/dl; HDL >50 mg/dl, Triglycerides <150 mg/dl Smoking Cessation AACE Diabetes Care Plan Guidelines. Endocr Pract. 2011;17(suppl 2). American Diabetes Association. Standards of Medical Care in Diabetes Mellitus Diabetes Care. 2012;35(suppl ): A1C: GERIATRIC CONSIDERATIONS Intensive glucose control (A1c <6.5%) has been linked to increased all-cause and cardiovascular mortality and hypoglycemia in elderly patients with T2DM How "tightly" to control geriatric patient's blood glucose needs to be individualized, based on: Patient's functional and cognitive status How well hypoglycemic symptoms are recognized How to respond to them and other disease states 1.American Diabetes Association. Standards of Medical Care in Diabetes Mellitus , Diabetes Care. 2012;35(suppl ): Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(suppl ):S265 S280. A1C: GERIATRIC CONSIDERATIONS A1c <8% is acceptable for frail elderly patients With duration of illness >10 years With comorbid conditions requiring combination medications For elderly patients with T2DM who are relatively healthy, attaining target goals for the following may be more important than normalized glycemic control Blood pressure Lipids Smoking cessation Diet and exercise 1. American Diabetes Association. Standards of Medical Care in Diabetes Mellitus , Diabetes Care. 2012;35(Suppl ): Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(Suppl Guidelines):S265 S280. 3
4 Antihyperglycemic therapy in type 2 diabetes: general recommendations. Principles of the AACE Algorithm for the Treatment of Type 2 DM Copyright 2012 American Diabetes Association, Inc. Inzucchi SE et al. Diabetes Care. 2012;35: OVERVIEW OF GUIDELINES DIFFERENCES ADA Last updated 2012 Metformin first-line drug Dual or triple therapy may be considered; however, many patients ultimately need insulin monotherapy or in combination with other medications AACE Last updated 2013 Metformin preferred first-line drug; however, other classes also used as monotherapy Dual or triple therapy preferred over insulin monotherapy or in combination with other medications ADA OVERVIEW OF GUIDELINES DIFFERENCES DPP-4 inhibitors not included in 2009 because effectiveness on glycemic control lower than or equivalent to other agents and cost; now can use, but patient should be close to A1c goal GLP-1 receptor agonists considered second-line agents AACE Favors use of GLP-1 receptor agonists and DPP-4 inhibitors with higher priority because of effectiveness and safety profiles DIABETES MEDICATION TIMELINE PHARMACOTHERAPY Insulin 1922 SUs 1957 Metformin Alpha-glucosidase inhibitor 1995 Symlin Sitagliptin Saxagliptin Linagliptin Alogliptin (Pramlintide) (Januvia) (Onglyza) (Tradjenta) (Nesina ) Amylinomimetic 2005 DPP DPP DPP DPP Meglitinides Thiazolidinediones 1997 Exenatide (Byetta) GLP Liraglutide (Victoza) GLP Extended Exenatide (Bydureon) GLP New Class Approval Philippe J, Raccah D. Int J Clin Pract. 2009;63(2): Patlak M. Breakthroughs in Bioscience
5 Targeted Sites of Diabetes Drug Classes Liver Biguanides TZDs Pancreas Hepatic glucose overproduction Glucose absorption issues Biguanides Sulfonylureas Meglitinides DDP-4 inhibitors GLP-1 receptor agonists Plasma Glucose Gut Alpha-glucosidase inhibitors DPP-4 Inhibitors GLP-1 receptor agonists Beta-cell dysfunction Buse JB. Williams Textbook of Endocrinology:10 th ed; Philadelphia, PA; WB Saunders; 2003: Muscle & Fat Insulin Resistance Biguanides TZDs DEFINITION OF INCRETINS Incretins are intestinal hormones released in response to meals; regulate insulin release. Creutzfeldt. Diabetologia. 1985;28:5645. In cret in Intestine Secretion Insulin INCRETIN PHYSIOLOGY GLP-1 (Glucagon-like peptide 1) Increases glucose-dependent insulin secretion from beta cells Decreases inappropriate glucagon secretion from alpha cells Increases B-cell growth and replication Slows gastric emptying and reduces food intake Degraded by DPP-4 enzyme Meal GIP (Glucose-dependent insulinotropic polypeptide) Increases glucose-dependent insulin release Degraded by DPP-4 enzyme 1. Drucker DJ, Nauck MA. Lancet. 2006;368: Nauck MA. Am J Med. 2009;122(uppl 1):S3-S10. Drawn in Inkscape by Ilmari Karonen based on w:image:incretins and DPP 4 inhibitors.jpg from GLP-1: EXENATIDE Exenatide: Analog of hormone incretin GLP-1 Hormone derived from saliva of Gila monster, poisonous lizard found in Southwestern US and Mexico Clinical Effect Immediate-release exenatide decreases A1c ~ 0.7% to 1% Extended-release exenatide decreases A1c 1.5% to 1.9% GLP-1 EXENATIDE Dose Immediate-release: Initial: 5 mcg twice daily SQ, within 60 minutes prior to a meal; after 1 month, may be increased to 10 mcg twice daily pen available Extended-release: 2 mg SQ once weekly vial only Combination therapy considerations Reduce dose of sulfonylureas when adding GLP-1 agents to therapy No changes to therapy if adding with metformin No dose adjustments in hepatic or renal dysfunction limited experience 1. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc. 2005; Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc. 2005; Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc
6 COMBINATION THERAPY: Exenatide and Insulin FDA approved exenatide as add-on therapy with insulin glargine, diet, and exercise for adult patients Exenatide group had 1.7% decrease in A1c levels, vs 1% drop in insulin-alone group (P <0.001) Body weight in patients receiving exenatide lower by 4 lb (avg) vs 2 lb increase in insulin-alone group Reductions in A1c in exenatide patients not associated with increase in hypoglycemia compared with insulin-alone group Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med. 2011;154: GLP-1: LIRAGLUTIDE Synthetic long-acting analog of human GLP-1 Clinical Effect: Liraglutide decreases A1c by ~ 1% Dosage: SQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily May increase to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg/day Available as pen No dose adjustments in hepatic or renal dysfunction limited experience Victoza [package insert]: Novo Nordisk. Princeton, NJ; COMBINATION OF LIRAGLUTIDE AND INSULIN DETEMIR Addition of insulin detemir to liraglutide and metformin helped decrease A1c by additional 0.5% after 1 year of therapy (P < ) Minor hypoglycemia seen in episodes/year among patients on combination of insulin, liraglutide, and metformin There were no adverse events that resulted in subject discontinuation from the study EXENATIDE ONCE WEEKLY VERSUS LIRAGLUTIDE ONCE DAILY IN PATIENTS WITH T2DM (DURATION-6) 26-week, open-label, randomized, parallel-group study at 105 sites in 19 countries in patients with T2DM Figure shows both drugs associated with a clinically important decrease in A1c from baseline. *P <0.0001; P =0.0005; P = ; P = Change in A1c (primary endpoint) was not significantly different in patients taking liraglutide than in those taking exenatide Morrow L, Hompesch M, Guthrie H, et al. Diabetes Obes Metab ;13(1): doi: /j Buse, JB, Nauck M, Forst T, et al. Lancet. 2013;12;381(9861): PHARMACIST COUNSELING POINTS WITH GLP- 1 AGONISTS Due to effects on gastric emptying, these agents may reduce rate and extent of absorption of orally administered drugs Administer medications 1 hour prior to use of immediaterelease exenatide or liraglutide Use with caution in patients receiving medications with narrow therapeutic window or those requiring rapid absorption from GI tract Postmarketing reports of increased INR; caution with concomitant use of warfarin and exenatide Immediate release exenatide only: Time of administration 60 minutes prior to meal PHARMACIST COUNSELING POINTS WITH EXENETIDE ER Exenetide ER Will likely affect drug absorption; use with caution Requires approximately 2 weeks of therapy before full effect Patient may see glucose elevations during this time Counseling point on missing doses If you miss a dose of BYDUREON, take it as soon as you remember, as long as the next dose is due at least three days later If you miss a dose and the next regularly scheduled dose is due one or two days later, do not take the missed dose but take BYDUREON on the next regularly scheduled day. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc. 2005;2008. Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc Victoza [package insert]: Novo Nordisk. Princeton, NJ; Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc
7 GLP-1 AGONIST SIDE EFFECTS Thyroid tumors: US Black Box Warning Dose- and duration-dependent thyroid C-cell tumors developed in animal studies with GLP-1 therapy; relevance in humans unknown During clinical studies, 5 cases of thyroid C-cell hyperplasia reported in rats Patients should be counseled on risk and symptoms (eg, neck mass, dysphagia, dyspnea, persistent hoarseness) of thyroid tumors Contraindicated in patients with or family history of medullary thyroid cancer (MTC) and in patients with multiple endocrine neoplasia syndrome type 2 (MEN2) GLP-1 AGONIST SIDE EFFECTS (CONT.) Pancreatitis Exenatide: 30 reports of acute pancreatitis and 6 reports of hemorrhagic or necrotizing pancreatitis 2 deaths, 4 recovered Conclusive evidence linking pancreatitis to liraglutide therapy not established Discontinue drug if pancreatitis suspected Symptoms such as pain in abdomen that is severe, will not go away. Pain that may happen with or without vomiting. Pain that is felt going from your abdomen through your back Do NOT re-challenge if pancreatitis diagnosed Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc. 2005;2008 Victoza [package insert]: Novo Nordisk. Princeton, NJ; Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc. 2005;2008 Victoza [package insert]: Novo Nordisk. Princeton, NJ; COMPARISON OF DPP-4 INHIBITORS DIPEPTIDYL PEPTIDASE-IV (DPP-4) INHIBITORS Drug Name Dosage Clinical Efficacy Metabolism/Excretion Sitagliptin 100 mg once daily *must be renally adjusted % A1c reduction Saxagliptin mg once daily % A1c reduction Linagliptin 5 mg once daily % A1c reduction Renal elimination many studies evaluating use in renal dysfunction Hepatic/Renal Excretion if giving concomitant with strong CYP3A4 inhibitors or patients with Scr <50ml/min give 2.5 mg once daily Hepatic use with caution with CYP3A4 inhibitors Alogliptin *Available in summer mg once daily % A1c reduction Renal elimination requires renal dose reduction 1. Januvia [package insert]: Merck. Whitehouse Station, NJ; Onglyza [package insert]: Bristol-Myers Squibb. Princeton, NJ; Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; Nesina [package insert]. Deerfield, IL: Tekeda Pharmaceutical Compay; 2013 DPP-4 INHIBITOR CLASS SIDE EFFECTS Hypersensitivity reactions: Rare hypersensitivity reactions Anaphylaxis, angioedema, Stevens-Johnson syndrome, reported in postmarketing surveillance Reports with both sitagliptin, saxagliptin and alogliptin No reports associated with linagliptin Discontinue if signs/symptoms of hypersensitivity reactions occur Events generally noted within first 3 months of therapy, and may occur with initial dose 1. Januvia [package insert]: Merck. Whitehouse Station, NJ; Onglyza [package insert]: Bristol-Myers Squibb. Princeton, NJ; Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; Nesina [package insert]. Deerfield, IL: Tekeda Pharmaceutical Compay; 2013 DPP-4 INHIBITOR CLASS SIDE EFFECTS (CONT.) Pancreatitis: Sitagliptin: Reported cases of acute pancreatitis (including hemorrhagic and necrotizing pancreatitis with some fatalities) Linagliptin: Pancreatitis reported in 8 of 4687 patients while being treated with linagliptin compared with 0 of 1183 patients treated with placebo Monitor for signs/symptoms of pancreatitis Discontinue use immediately if pancreatitis suspected Alogliptin reports post-marketing cases of pancreatitis Saxagliptin: None reported but thought to be potential class effect 1. Januvia [package insert]: Merck. Whitehouse Station, NJ; Onglyza [package insert]: Bristol-Myers Squibb. Princeton, NJ; Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; Nesina [package insert]. Deerfield, IL: Tekeda Pharmaceutical Compay;
8 DPP-4 INHIBITOR PHARMACIST COUNSELING POINTS Combination therapy considerations: Can continue current metformin dosage Reduce dose of sulfonylureas recommended Reduce dose of insulin recommended Dose reductions should be made in patients with renal dysfunction: Sitagliptin Saxagliptin Alogliptin Caution with concomitant use with strong CYP3A4 inhibitors: Saxagliptin Linagliptin FUTURE THERAPIES: SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT2) INHIBITORS 1. Januvia [package insert]: Merck. Whitehouse Station, NJ; Onglyza [package insert]: Bristol-Myers Squibb. Princeton, NJ; Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; Nesina [package insert]. Deerfield, IL: Tekeda Pharmaceutical Compay; 2013 FUTURE THERAPIES: SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT2) INHIBITORS Renal Handling of Glucose, Non-Diabetic Individual SGLT2 is a low-affinity, high-capacity transporter requiring 1 glucose and 1 sodium molecule. SGLT2 in the kidney plays a critical role in the reabsorption of glucose. It is almost exclusively found in the S1 segment of the proximal renal tubule; accounts for ~ 90% of the renal reabsorption of glucose (180 grams of glucose/day) Breakdown: blocks reabsorption of glucose by the kidney and increases excretion of glucose in urine S1 part of proximal tubule Glucose filtered/day = 180 g Reabsorption Glucose SGLT2 ~90% ~10% S G L T 1 Virtually all the glucose filtered is reabsorbed and glucose does not appear in the urine. Collecting duct S3 part of proximal tubule SGLT, Sodium-glucose cotransporter NO GLUCOSE Neumiller JJ, White JR, Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70: Wright EM. Am J Physiol Renal Physiol. 2001;280:F10-F18. Thorens B. Am J Physiol. 1996;270:G541-G553. SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT2) INHIBITORS First drug in class, dapagliflozin, rejected by FDA in January 2012 Concerned drug raised risk of bladder and breast cancer in 11 phase III clinical trials Second drug, canagliflozin (Invokana) received FDA approval on March 29, 2013 A third SGLT2 inhibitor, ipragliflozin (Astellas Pharma) has been filed for marketing approval in Japan, and a fourth, empagliflozin (Eli Lilly/Boehringer Ingelheim), is in phase 3 trials and has just been filed for approval in the United States. Canagliflozin (Invokana) 26-week, randomized, double-blind, placebo-controlled, phase 3 trial 584 adult subjects with T2DM received canagliflozin 100 or 300 mg or placebo once daily. At week 26, canagliflozin 100 and 300 mg (compared with placebo) significantly reduced A1C from baseline, ( 0.77, 1.03 and 0.14%, respectively; p<0.001 for both). Adverse events The incidence of genital mycotic infections was higher with canagliflozin compared with placebo There incidence of urinary tract infections was higher with canagliflozin compared with placebo The percentage of subjects with documented hypoglycaemia was similar with canagliflozin 100 and 300 mg and placebo (3.6, 3.0 and 2.6%, respectively), with no report of severe hypoglycaemia. FDA Rejects Dapagliflozin for Type 2 Diabetes By Emily P. Walker, Washington Correspondent, MedPage Today Hardman TC, Dubrey SW. Development and Potential Role of Type-2 Sodium-Glucose Transporter Inhibitors for Management of Type 2 Diabetes. Diabetes Therapy (2011) 2(3): Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):
9 CLINICAL INERTIA Defined as failure to intensify treatment of a patient who is not at evidence-based A1c goal Clinical inertia postulated as major barrier to better diabetes care Concern of clinical inertia focusing too closely on sole glucose control; may divert attention from other diabetes quality measures such as blood pressure and LDL control All healthcare providers should be aware of clinical inertia and focus on optimizing all patient outcomes PRINCIPLES OF COMBINATION THERAPY SELECTION Early vs late disease How much A1c lowering needed? Patients with frequent hypoglycemia events? Intolerable side effects Safety profiles Too costly? Insurance coverage? Nonadherence to multiple self-monitoring blood glucose values Ease of use Frequency Injectable vs noninjectable Berlowitz DR, Ash AS, Glickman M, Friedman RH, Pogach L, Nelson AL. Developing a Quality of Measure for Clinical Inertia in Diabetes Care Health Services Research doi: /j x available online at Nathan DM et al. Diabetes Care. 2009; 32: PATIENT CASE # 1 JP is a 62-year-old female with an 2-year history of T2DM. Current A1c = 7.4% Serum creatinine = 1.1 mg/dl; CrCl = 65 ml/min - Body mass index = 30 Current DM therapy includes: Metformin ER 2000 mg daily and Glipizide 20 mg XL daily Question: What changes should be made to DS s T2DM therapy? A) Continue with current therapy and lifestyle changes B) Add sitagliptin (DPP-4) and reduce dose of glipizide C) Add exenatide (GLP-1) and reduce dose of glipizide D) Add basal insulin and discontinue glipizide TACTICS TO IMPROVE PATIENT ADHERENCE Find that teachable moment : Explain how medication would benefit patient Explain goals of diabetes control Explain how patients are in control of their outcomes Identify barriers to adherence: Do patients need to demonstrate injection technique? Are patients concerned about side effects? Is it too expensive? Are they spreading out their supply Encourage, Motivate, Encourage Questions THANK YOU 9
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More information2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists
WAYNE STATE UNIVERSITY COLLEGE OF PHARMACY & HEALTH SCIENCES FEBRUARY 28, 2016 The Evolving Armamentarium for Type 2 Diabetes: Clinical Assistant Professor, Department of Pharmacy Practice Ambulatory Care
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationIndividualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD
Individualizing Type 2 Diabetes Management Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Harsh Statistics 30.3 million (9.4% of population) in US had DM in 2015 The percent of population with DM increases
More information3/22/2017. Type 2 Diabetes Pathophysiology and Pharmacology Review. Accreditation Statement
Type 2 Diabetes Pathophysiology and Pharmacology Review Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA This
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationPharmacologic Agents for Treatment of Type 2 Diabetes
Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationExploring Non-Insulin Therapies in Type 1 Diabetes
Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationDate of Review: September 2016 Date of Last Review: September 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action
Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationExploring Non-Insulin Therapies in Type 1 Diabetes. Objectives. Pre-Assessment Question #1. Disclosures
Exploring Non-Insulin Therapies in Type 1 Diabetes Disclosures Dr. Cornell: Advanced Practitioner Advisory Board and Speakers Bureau: Novo Nordisk Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationDiabetes Mellitus. Intended Learning Objectives:
Intended Learning Objectives: Diabetes Mellitus 1. Compare and contrast the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines. 2. Assess the
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationDIABETES UPDATE 2018
DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationPlease Complete the Pre-Activity Survey
Please Complete the Pre-Activity Survey This activity is supported through an educational grant from Novo Nordisk. Learning Objectives Upon completion of this educational activity, the participant should
More information